Cost effectiveness of sodium-glucose cotransporter-2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and dipeptidyl peptidase-4 (DPP-4) …

D Hong, L Si, M Jiang, H Shao, W Ming, Y Zhao… - …, 2019 - Springer
Objective This study aimed to systematically review cost-effectiveness studies of newer
antidiabetic medications. Methods The PubMed/MEDLINE, EMBASE, CINAHL Plus …

When to use discrete event simulation (DES) for the economic evaluation of health technologies? A review and critique of the costs and benefits of DES

J Karnon, H Haji Ali Afzali - Pharmacoeconomics, 2014 - Springer
Modelling in economic evaluation is an unavoidable fact of life. Cohort-based state transition
models are most common, though discrete event simulation (DES) is increasingly being …

[PDF][PDF] Declining liver graft quality threatens the future of liver transplantation in the United States

ES Orman, ME Mayorga, SB Wheeler… - Liver …, 2015 - Wiley Online Library
National liver transplantation (LT) volume has declined since 2006, in part because of
worsening donor organ quality. Trends that degrade organ quality are expected to continue …

Novel risk engine for diabetes progression and mortality in USA: building, relating, assessing, and validating outcomes (BRAVO)

H Shao, V Fonseca, C Stoecker, S Liu, L Shi - Pharmacoeconomics, 2018 - Springer
Background There is an urgent need to update diabetes prediction, which has relied on the
United Kingdom Prospective Diabetes Study (UKPDS) that dates back to 1970 s' European …

The cost‐effectiveness of dapagliflozin in treating high‐risk patients with type 2 diabetes mellitus: an economic evaluation using data from the DECLARE‐TIMI 58 trial

P McEwan, AR Morgan, R Boyce… - Diabetes, Obesity …, 2021 - Wiley Online Library
Aim To undertake a cost‐effectiveness analysis of dapagliflozin in treating high‐risk patients
with type 2 diabetes mellitus (T2DM), using both directly observed events in the DECLARE …

Cost-effectiveness of newer antidiabetic drugs as second-line treatment for type 2 diabetes: a systematic review

J Zhu, Y Zhou, Q Li, G Wang - Advances in Therapy, 2023 - Springer
Introduction Evidence from cardiovascular outcome trials (CVOTs) for newer antidiabetic
drugs is increasingly influencing revised recommendations for second-line therapy in type 2 …

Operations research in global health: a scoping review with a focus on the themes of health equity and impact

BD Bradley, T Jung, A Tandon-Verma, B Khoury… - Health research policy …, 2017 - Springer
Background Operations research (OR) is a discipline that uses advanced analytical methods
(eg simulation, optimisation, decision analysis) to better understand complex systems and …

Cost effectiveness of dipeptidyl peptidase-4 inhibitors for type 2 diabetes

J Geng, H Yu, Y Mao, P Zhang, Y Chen - Pharmacoeconomics, 2015 - Springer
Abstract Background Dipeptidyl peptidase-4 (DPP-4) inhibitors are a new class of
antidiabetic drugs used for treating type 2 diabetes mellitus. While many studies have …

A pharmacoeconomic analysis to compare cost-effectiveness of metformin plus teneligliptin with metformin plus glimepiride in patients of type-2 diabetes mellitus

T Tandon, AK Dubey, S Srivastava… - Journal of Family …, 2019 - journals.lww.com
Background: With the available evidence of early combined oral drug therapies being more
effective in lowering blood glucose levels than maximal doses of a single drug, many …

[HTML][HTML] Adverse drug events in cost-effectiveness models of pharmacological interventions for diabetes, diabetic retinopathy, and diabetic macular edema: a scoping …

M Pesonen, V Jylhä, E Kankaanpää - JBI Evidence Synthesis, 2024 - journals.lww.com
Objective: The objective of this review was to examine the role of adverse drug events
(ADEs) caused by pharmacological interventions in cost-effectiveness models for diabetes …